Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

A year of open-label raloxifene extended the study to assess the response with and without delay after discontinuation of teriparatide.

Why It Was Studied

Loss of bone mineral density occurs after discontinuation of teriparatide, if no subsequent treatment is given.

Who Took Part

The age groups tagged for this paper are older adults, women only.

How the Study Was Run

The researchers set it up as a randomized, open-label and placebo-controlled study.

The participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Everyone knew when Teriparatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Some participants received a placebo instead of Teriparatide, giving a reference point.

BMD was measured by dual energy x-ray absorptiometry.

What Was Measured

Topics PubMed links to this paper include Australia, Bone Density, Bone Density Conservation Agents, Canada, Europe, Femur Neck and Lumbar Vertebrae.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Teriparatide.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Teriparatide compound page, all human trials.